Beta

Centessa pharmaceuticals plcCNTA.US Overview

US StockHealthcare
(No presentation for CNTA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CNTA AI Insights

CNTA Overall Performance

CNTA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CNTA Recent Performance

-0.13%

Centessa pharmaceuticals plc

-1.10%

Avg of Sector

-0.49%

S&P500

CNTA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CNTA's Trend

CNTA Key Information

CNTA Valuation Metrics

CNTA Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Price of CNTA

CNTA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CNTA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
406.97
PB Ratio
11.59
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1316.88%
Revenue Growth (YoY)
118.88%
Profit Growth (YoY)
118.88%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
406.97
PB Ratio
11.59
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1316.88%
Revenue Growth (YoY)
118.88%
Profit Growth (YoY)
118.88%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CNTA's latest earnings report released?

    The most recent financial report for Centessa pharmaceuticals plc (CNTA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CNTA's short-term business performance and financial health. For the latest updates on CNTA's earnings releases, visit this page regularly.

  • How much cash does CNTA have?

    At the end of the period, Centessa pharmaceuticals plc (CNTA) held Total Cash and Cash Equivalents of 61.3M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CNTA's EPS continuing to grow?

    According to the past four quarterly reports, Centessa pharmaceuticals plc (CNTA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CNTA?

    Centessa pharmaceuticals plc (CNTA)'s Free Cash Flow (FCF) for the period is -55.82M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 30.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CNTA?

    The latest valuation data shows Centessa pharmaceuticals plc (CNTA) has a Price-To-Earnings (PE) ratio of -31.08 and a Price/Earnings-To-Growth (PEG) ratio of -0.88. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.